BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dusheiko G. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver Int. 2017;37 Suppl 1:7-12. [PMID: 28052638 DOI: 10.1111/liv.13292] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Silva LD, Bering T, Rocha GA. The impact of nutrition on quality of life of patients with hepatitis C. Curr Opin Clin Nutr Metab Care 2017;20:420-5. [PMID: 28617708 DOI: 10.1097/MCO.0000000000000396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Serper M, Evon DM, Amador J, Stewart PW, Sarkar S, Lok AS, Sterling RK, Reeve BB, Golin CE, Rajender Reddy K, Lim JK, Reau N, Nelson DR, Di Bisceglie AM, Fried MW. Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int 2021;41:692-704. [PMID: 33387381 DOI: 10.1111/liv.14781] [Reference Citation Analysis]
3 Marcellin P, Estrabaud E. Recent advances in hepatology. Liver Int 2017;37:3-6. [DOI: 10.1111/liv.13323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
4 Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Dig Liver Dis 2019;51:915-21. [PMID: 31031174 DOI: 10.1016/j.dld.2019.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Höner Zu Siederdissen C, Schlevogt B, Solbach P, Port K, Cornberg M, Manns MP, Wedemeyer H, Deterding K. Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. Liver Int 2018;38:834-41. [PMID: 28960793 DOI: 10.1111/liv.13601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
7 Kwo PY, Shiffman ML, Bernstein DE. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. American Journal of Gastroenterology 2018;113:2-4. [DOI: 10.1038/ajg.2017.420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Vieira DA, da Cunha LR, da Silva CB, Almeida MTB, Gomes AD, de Faria CLL Jr, Teixeira R, Neves FS, Rocha GA, de Melo FF, de Magalhães Queiroz DM, Silva LD. The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C. Qual Life Res 2019;28:1531-42. [PMID: 30734130 DOI: 10.1007/s11136-019-02129-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
11 Juanbeltz R, Martínez-Baz I, San Miguel R, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One 2018;13:e0205277. [PMID: 30300395 DOI: 10.1371/journal.pone.0205277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
12 Juanbeltz R, Castilla J, Martínez-Baz I, O'Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res 2019;28:1477-84. [PMID: 30666549 DOI: 10.1007/s11136-019-02111-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Koretz RL, Jakobsen JC, Djurisic S, Poropat G, Hauser G, Bjelakovic M, Bjelakovic G, Gluud C. Who is wrong? Responses to Kwo et al. Am J Gastroenterol 2018;113:779-80. [PMID: 29487409 DOI: 10.1038/s41395-018-0029-4] [Reference Citation Analysis]
14 Cunha LRD, Vieira DA, Giampietro YG, Gomes AD, Lopes de Faria CL Jr, Freire de Melo F, Teixeira R, Teixeira de Carvalho A, Oliveira LM, Filho OAM, Rocha GA, Maria de Magalhães Queiroz D, Neves FS, Silva LD. Interleukin-10 promoter gene polymorphisms are associated with the first major depressive episode in chronic hepatitis C patients. Clin Res Hepatol Gastroenterol 2019;43:417-26. [PMID: 30591371 DOI: 10.1016/j.clinre.2018.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785-792. [PMID: 30227916 DOI: 10.1016/j.jhep.2018.05.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
16 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Pariente A, Arpurt JP, Rémy AJ, Rosa-Hézode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le eaBricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagège H, Lesgourgues B; Association nationale des gastroentérologues des hôpitaux (ANGH). Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH). Presse Med 2019;48:e101-10. [PMID: 30853287 DOI: 10.1016/j.lpm.2018.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Sadeghimehr M, Bertisch B, Negro F, Butsashvili M, Shilton S, Tskhomelidze I, Tsereteli M, Keiser O, Estill J. Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis. PeerJ 2021;9:e11895. [PMID: 34595063 DOI: 10.7717/peerj.11895] [Reference Citation Analysis]
19 Mariño Z, Rodríguez-Tajes S, Bartrés C, Nácar L, Lens S, Navinés R, Cavero M, Londoño MC, Sastre L, Pocurull A, Dafieno A, Martín-Santos R, Forns X. Improvement of sexuality after hepatitis C cure with direct acting antivirals. Liver Int 2020;40:2972-7. [PMID: 33025664 DOI: 10.1111/liv.14689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]